METHOD DEVELOPMENT AND VALIDATION OF ERYTHROMYCIN AND OLAPARIB IN HUMAN PLASMA BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY

PAGIDI RAJAGOPALUDU; NIMMAKAYALA SARITHA; DEVANNA N; SRINIVAS MADDI

doi:10.22159/ajpcr.2022.v15i4.44044

Authors

PAGIDI RAJAGOPALUDU Department of Chemistry, Jawaharlal Nehru Technological University, Anantapur, Andhra Pradesh, India. https://orcid.org/0000-0002-5226-9285
NIMMAKAYALA SARITHA Department of Chemistry, Jawaharlal Nehru Technological University College of Engineering, kalikiri, Chittoor, Andhra Pradesh, India.
DEVANNA N Department of Chemistry, Jawaharlal Nehru Technological University, Anantapur, Andhra Pradesh, India.
SRINIVAS MADDI AcuBioSys private Limited, Hyderabad, Telangana, India.

DOI:

https://doi.org/10.22159/ajpcr.2022.v15i4.44044

Keywords:

Erythromycin, Olaparib, Human plasma, Liquid chromatography–tandem mass spectrometry, Electrospray Ionization

Abstract

The liquid chromatography–tandem mass spectrometry (LC-MS)/MS methodology was used to develop and validate a method for detecting erythromycin and olaparib in human plasma. Antibiotics such as erythromycin and olaparib fall into this category. Liquid chromatography is used to separate stationary and mobile phases based on differences in their affinities as well as to remove unwanted contaminants. It improves repeatability, sensitivity, resilience, and low-level protein detection. A C18 (C18, 5 m, 100×4.6 mm) column is utilized for high resolution and peak area. The calibration curve is created using linear regression. Internally, telmisartan is utilized as a benchmark. The flow rate of the mobile phase is 0.5 mL/min. Erythromycin and olaparib have mass-to-charge ratios of 735.43–115.97 and 435.08–102.04, respectively. Erythromycin in combination with olaparib resulted in a 98% recovery rate. The precision and accuracy of the results determined by interday QC samples are within acceptable limits. There was no evidence of instability.

Downloads

Download data is not yet available.

References

Amin MM, Zilles JL, Greiner J, Charbonneau S, Raskin L, Morgenroth E. Influence of the antibiotic erythromycin on anaerobic treatment of a pharmaceutical wastewater. Environ Sci Technol 2006;40:3971-7. doi: 10.1021/es060428j, PMID 16830570

Washington CR, Richardson DL, Moore KN. Olaparib in the treatment of ovarian cancer. Future Oncol 2019;15:3435-49. doi: 10.2217/fon- 2019-0271, PMID 31478762

Anindya B. Development and validation of UV spectrophotometric method for estimation of erythromycin in bulk drug and pharmaceutical formulation. Int Adv Pharm 2015;5:71-6.

Rathore A, Lohidasan S, Mahadik K. Validated HPTLC method for simultaneous estimation of isotretinoin and erythromycin in bulk drug and topical gel form. Am J Anal Chem 2010;1:144-9. doi: 10.4236/ ajac.2010;13018

Taninaka C, Ohtani H, Hanada E, Kotaki H, Sato H, Iga T. Determination of erythromycin, clarithromycin, roxithromycin, and azithromycin in plasma by high-performance liquid chromatography with amperometric detection. J Chromatogr B Biomed Sci Appl 2000;738:405-11. doi: 10.1016/S0378-4347(99)00512-5

Stubbs C, Haigh JM, Kanfer I. Determination of erythromycin in serum and urine by high-performance liquid chromatography with ultraviolet detection. J Pharm Sci 1985;74:1126-8. doi: 10.1002/jps.2600741027, PMID 4078714

Mahmoudi A, Boukhechem MS. Novel liquid chromatographic method for the simultaneous evaluation of erythromycin and azithromycin in human urine. J Mater Environ Sci 2017;8:1953-9.

Li YX, Neufeld K, Chastain J, Curtis A, Velagaleti P. Sensitive determination of erythromycin in human plasma by LC-MS/ MS. J Pharm Biomed Anal 1998;16:961-70. doi: 10.1016/s0731- 7085(97)00095-2, PMID 9547699

Xiao W, Chen B, Yao S, Cheng Z. Simultaneous determination of erythromycin propionate and base in human plasma by high-performance liquid chromatography-electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;817:153-8. doi: 10.1016/j.jchromb.2004.11.055, PMID 15686979

Gu Y, Wang G, Sun J. Simultaneous determination of erythromycin ethylsuccinate and its metabolite erythromycin in human plasma using liquid chromatography-electrospray ionization mass spectrometry for clinical study. J Pharm Biomed Anal 2006;40:737-43. doi: 10.1016/j. jpba.2005.11.005, PMID 16376051

Daumar P, Dufour R, Dubois C, Penault-Llorca F, Bamdad M, Mounetou E. Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells. J Pharm Biomed Anal 2018;152:74- 80. doi: 10.1016/j.jpba.2018.01.036. PMID 29414021

Krens SD, van der Meulen E, Jansman FG, Burger DM, van Erp NP. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC–MS/MS. Biomed Chromatogr 2019;34:1- 12. doi: 10.1002/bmc.4758

Nijenhuis CM, Lucas L, Rosing H, Schellens JH, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying Olaparib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2013;940:121-5. doi: 10.1016/j.jchromb.2013.09.020, PMID 24145016

Jolibois J, Schmitt A, Royer B. A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2019;1132:121844. doi: 10.1016/j.jchromb.2019.121844, PMID 31678788

Roth J, Peer CJ, Mannargudi B, Swaisland H, Lee JM. A sensitive and robust ultra HPLC assay with tandem mass spectrometric detection for the quantitation of the PARP inhibitor olaparib in human plasma for pharmacokinetic application. Chromatography 2014;1:82-95. doi: 10.3390/chromatography1020082